Factors controlling epidermal growth factor (EGF) gene expression in the endometrium of the mare.
Previous studies showed a dramatic increase in EGF gene expression in the endometrial glands of pregnant mares around day 40 after ovulation. To investigate how the steroid hormones of pregnancy might regulate this expression, in situ hybridization was used to monitor the levels of EGF mRNA in endometrial biopsies obtained from seasonally anoestrous or ovariectomised mares given exogenous progesterone and oestrogen, alone or in combination, for up to 46 days. Biopsies were also taken from mares during the non-pregnant cycle, during normal pregnancies and pregnancies compromised by endometrial pathology (endometriosis) or because of incompatible extraspecific embryo transfers (donkey-in-horse pregnancies). Only a few samples showed weak EGF expression during the late luteal phase of the oestrous cycle. During normal pregnancy, the previously observed dramatic increase of expression after day 40 of gestation was confirmed. Although aged mares suffering from endometriosis and mares carrying an extraspecific donkey conceptus showed the same increase of EGF mRNA in normal glands, this was virtually absent from gland cross-sections compromised due to inflammatory or fibrotic changes. Administration of various doses and combinations of progesterone and oestrogen for < 35 days yielded negative or only weakly positive hybridization results, whereas progesterone alone for > or = 40 days upregulated EGF expression strongly irrespective of additional treatment with oestrogen. This is the first experimental evidence that EGF expression in the endometrium can be induced by progesterone alone. The requirement for prolonged progesterone priming is of considerable interest in the context of the unusually late stage of gestation at which placental attachment commences in equids.
Gerstenberg
C
C
University of Cambridge Department of Clinical Veterinary Medicine, Newmarket, Suffolk, United Kingdom.
Allen
W R
WR
Stewart
F
F
D000818:Animals; D004717:Endometrium / Q000378:metabolism* / Q000473:pathology; D004815:Epidermal Growth Factor / Q000235:genetics*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006736:Horses / Q000235:genetics* / Q000378:metabolism; D017403:In Situ Hybridization; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000235:genetics*; D011374:Progesterone / Q000378:metabolism* / Q000494:pharmacology
C074283:estradiol 3-benzoate; D011374:Progesterone; D004958:Estradiol; D004815:Epidermal Growth Factor